DEPARTMENT OF HEALTH AND

Centers for Disease Control and

Disease, Disability, and Injury

(PA) PAR07-231, Panel B

Control and Prevention (CDC)

15, 2007 (Closed).

telephone 404-264-1111.

Prevention and Control Special

Emphasis Panel (SEP): Centers for

Grants for Public Health Research

the Federal Advisory Committee Act

Disease Control and Prevention (CDC)

Dissertation, Program Announcement

In accordance with section 10(a)(2) of

(Pub. L. 92-463), the Centers for Disease

announces the aforementioned meeting.

Time and Date: 8 a.m.-4 p.m., November

Status: The meeting will be closed to the

U.S.C., and the Determination of the Director,

Place: Crowne Plaza Buckhead, 3377

Peachtree Road, NE., Atlanta, GA 30326,

public in accordance with provisions set

forth in section 552b(c)(4) and (6), Title 5

HUMAN SERVICES

Prevention

Ethics, Suite 500, 1201 New York Avenue, NW., Washington, DC 20005-3917: Telephone: 202-482-9300: TDD: 202-208-9293; FAX: 202-482-9237.

SUPPLEMENTARY INFORMATION: 5 U.S.C. 4314(c) requires each agency to establish, in accordance with regulations prescribed by the Office of Personnel Management at 5 CFR part 430, subpart C and § 430.310 thereof in particular, one or more Senior Executive Service performance review boards. As a small executive branch agency, OGE has just one board. In order to ensure an adequate level of staffing and to avoid a constant series of recusals, the designated members of OGE's SES Performance Review Board are being drawn, as in the past, in large measure from the ranks of other agencies. The board shall review and evaluate the initial appraisal of each OGE senior executive's performance by his or her supervisor, along with any recommendations in each instance to the appointing authority relative to the performance of the senior executive. This revised notice updates the membership of OGE's SES Performance Review Board as it was most recently published at 72 FR 53773–53774 (September 20, 2007), in order to reflect the appointment of one new member from another agency to replace a member from an agency who was not able to serve on OGE's board this year.

Approved: September 21, 2007.

Robert I. Cusick,

Director, Office of Government Ethics.

The following officials have been appointed as regular members of the SES Performance Review Board of the Office of Government Ethics:

- Marilyn L. Glynn [Chair], General Counsel, Office of Government Ethics
- Daniel D. Dunning [Alternate Chair], Deputy Director for Administration and Information Management, Office of Government Ethics
- Daniel L. Koffsky, Special Counsel, Office of Legal Counsel, Department of Justice

David Maggi, Chief, Ethics Law and Programs Division, Office of the Assistant General Counsel for Administration, Department of Commerce: and

Robert A. Shapiro, Associate Solicitor for Legal Counsel, Department of Labor

[FR Doc. E7-18973 Filed 9-25-07; 8:45 am] BILLING CODE 6345-02-P

Management Analysis and Services Office, CDC, pursuant to Public Law 92-463. Matters To Be Discussed: The meeting will include the review, discussion, and

evaluation of "CDC Grants for Public Health Research Dissertation," PA PAR07-231, Panel B.

Contact Person for More Information: Susan B. Stanton, D.D.S., Scientific Review Administrator, Office of the Chief Science Officer, CDC, 1600 Clifton Road, NE., Mailstop D 72, Atlanta, GA 30333, Telephone 404-639-4640.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 20, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7-18945 Filed 9-25-07; 8:45 am] BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury **Prevention and Control Special Emphasis Panel (SEP): Centers for Disease Control and Prevention (CDC) Grants for Public Health Research Dissertation, Program Announcement** (PA) PAR07-231, Panel C

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Date: 8:30 a.m.-4 p.m., November 16, 2007 (Closed).

Place: Crowne Plaza Buckhead, 3377 Peachtree Road, NE., Atlanta, GA 30326, telephone 404-264-1111.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of "CDC Grants for Public Health Research Dissertation," PAR07–231, Panel C.

Contact Person for More Information: Sheree Marshall Williams, Ph.D., M.Sc., Scientific Review Administrator, Office of the Chief Science Officer, CDC, 1600 Clifton Road, NE., Mailstop D 72, Atlanta, GA 30333, Telephone 404-639-4896.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 20, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7-18947 Filed 9-25-07; 8:45 am] BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute: Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.s.C., as amended, because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: President's Cancer Panel.

Date: October 22, 2007.

Open: October 22, 2007, 8 a.m.–4 p.m. *Agenda:* Strategies for Maximizing the Nation's Investment in Cancer.

Place: Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, CA 92122.

Closed: October 22, 2007, 4:30 p.m.–6:30 p.m.

Agenda: The Panel will discuss potential recommendations from current series "Strategies for Maximizing the Nation's Investment in Cancer" and discuss potential topics for the 2008/2009 series.

Place: Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, CA 92122.

Contact Person: Abby Sandler, Ph.D, Executive Secretary, National Cancer Institute, National Institutes of Health, Building 6116, Room 212, 6116 Executive Boulevard, Bethesda, MD 20892, 301/451/ 9399.

Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: *deainfo.nci.nih.gov/advisory/pcp/pcp.htm*, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research, 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: September 18, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–4739 Filed 9–25–07; 8:45am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel, NIMH Brainbank Review.

Date: October 15, 2007.

Time: 12 p.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: David M. Armstrong, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center/ Room 6138/MSC 9608, 6001 Executive Boulevard, Bethesda, MD 20892–9608, 301– 443–3534, armstrda@mail.nih.gov.

Name of Committee: National Institute of Mental Health Special Emphasis Panel, Adult DCISIR & ACISIR Centers.

Date: November 13, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriot North Bethesda Convention Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Marina Broitman, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9608, Bethesda, MD 20892–9608, 301–402–8152, *mbroitma@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: September 18, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4737 Filed 9–25–07; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Disease; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Rheumatic Disease Clinical Trial.

Date: October 2, 2007.

Time: 2 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications. *Place:* National Institutes of Health,

Democracy One, 6701 Democracy Boulevard, 800, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Kan Ma, PhD, Scientific Review Administrator, NIH/NIAMS, EP Review Branch, One Democracy Plaza Suite 800, Bethesda, MD 20892–4872, 301–594– 4952, *mak2@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Musculoskeletal Diseases Clinical Trial Planning Grants.

Date: October 9, 2007.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Kan Ma, PhD, Scientific Review Administrator, NIH/NIAMS, EP Review Branch, One Democracy Plaza Suite